Michael Bookman
CLO Immuneering Corp.
Seminars
Wednesday 5th August 2026
Panel Discussion: Strengthening IPO Readiness to Reduce Liability Exposure & Support Defensible Board Decision‑Making
3:15 pm
- Build disclosure discipline early by aligning scientific claims, press releases, BD decks, and public statements to withstand S‑1 scrutiny
- Reduce litigation and enforcement risk through structured risk‑factor design and clear escalation controls
- Strengthen board decision‑making with disciplined go/no‑go criteria, documentation standards, and scenario pathways
- Prepare for life as a public company by aligning IPO readiness with post‑IPO ongoing public company obligations, capital markets strategy, contingency planning, and dual‑track financing scenarios
Thursday 6th August 2026
Panel Discussion: Practical Considerations in Cross-Border Transactions Amid Geopolitical & Market Uncertainty
2:10 pm
- Evaluate how public policy shifts, geopolitical uncertainty, and changes across the international biopharma landscape are reshaping transaction structures, negotiations, and deal execution
- Future-proof cross-border transactions by building flexibility into deal terms, governance frameworks, and risk allocation mechanisms amid continued market uncertainty
- Strengthen diligence and decision-making when evaluating international assets, partners, and opportunities while preparing for emerging trends in cross-border dealmaking
